Benefits
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin, deliberately engineered to remove EPO's red-blood-cell-stimulating activity while keeping the tissue-protective signaling — meaning it doesn't carry the cardiovascular risk associated with elevated hematocrit that full EPO does.
Rat model (spared nerve injury): dose-dependent relief of both mechanical and cold allodynia lasting up to 20 weeks, coupled with suppression of the spinal microglia response at a 30μg/kg dose. Swartjes et al., Mol Pain, 2014 This paper's own discussion cites real prior human results: "chronic ARA 290 administration reduced pain symptoms and improved functionality in patients with chronic neuropathic pain related to small fiber neuropathy" (referencing a 2013 human trial in sarcoidosis-associated small fiber neuropathy). ARA-290 holds FDA orphan drug status but was never approved, and development has largely stalled.
Dosage
The verified rat dose was 30μg/kg. Human trial dosing referenced in secondary reporting (4mg subcutaneous daily) wasn't independently re-verified against its primary source in this research pass — worth confirming directly before treating as established.
Can Ara-290 help with neuropathy?+
There's real science behind the idea, even if it's not a cure. Ara-290 is a non-erythropoietic peptide derived from EPO, meaning it's designed to skip EPO's blood-thickening side effects (the ones tied to stroke and heart attack risk) while keeping its nerve-protective activity.
That nerve-protective angle has real clinical research behind it in diabetic nerve pain specifically, which is where most of the neuropathy interest traces back to.
Can Ara-290 cure my retinopathy?+
'Cure' is too strong a word for where the research actually is. In animal studies, it showed promise for protecting against vascular leakage and retinal damage linked to diabetic retinopathy, but that's animal-level evidence, not a proven human treatment, and there's currently no active clinical pathway pushing it further (more on that below).
Why is Ara-290 so expensive compared to other peptides?+
Scarcity, mostly. The company that originally developed it, Araim Pharmaceuticals, shut down entirely in 2026, and there's no active FDA pathway for it anymore.
That means it's no longer produced at real pharmaceutical scale — what's available now comes from a small handful of specialty research suppliers, and that scarcity shows up directly in the price.
Ara-290 is hard to reconstitute — why, and how do you do it?+
Because it won't actually dissolve in plain water — it needs a phosphate-buffered saline solution to go into solution properly.
Some suppliers ship it with that buffer already in the vial, which makes it dissolve easily once you add bacteriostatic water. If yours didn't come with one, that's the piece you're missing.
Looking for something specific, or placing a wholesale order? Send us a DM or email.